USP and Public Policy
Left
Refine Your Search
101 signatures, including USP, wrote to express the collective strong desire to see the Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorized before the end of the calendar year in the same…
Learn More
USP Comment Letter to Senators Sanders and Cassidy and Representatives McMorris-Rodgers and Pallone ( ranking members of the Senate HELP Committee and House Energy and Commerce Committee) regarding…
Learn More
USP is pleased to provide a response to the bicameral Request for Information (RFI) on the increase in drug shortages. Submitted July 7, 2023.
Learn More
The United States Pharmacopeia (USP) is pleased to offer its support for the “Mapping America’s Pharmaceutical Supply Act” (S. 2364), or the MAPS Act.
Learn More
USP supports a comprehensive public policy framework to combat substandard and falsified medicines, including advancing stewardship of quality pharmaceutical products and practices, and building the…
Learn More
USP is pleased to submit feedback to the Senate HELP Committee on the bipartisan discussion draft to reauthorize the Pandemic and All-Hazards Preparedness Act (PAHPA).
Learn More
USP is please to provide a response to the Senate Committee on Health, Education, Labor, and Pensions (HELP) Request for Information on policies related to the Pandemic and All-Hazards Preparedness…
Learn More
USP appreciate the opportunity to respond to the request for information (RFI) from the Office of Science and Technology Policy (OSTP) on the National Biotechnology and Biomanufacturing Initiative.
Learn More
A resilient supply chain withstands acute disruptions so that safe, effective, and quality medicines can be supplied to patients around the globe, in adequate quantities, when they are needed. Poster…
Learn More
USP appreciates the opportunity to provide comments on ACIL’s “Guide to a Harmonized National Cannabis Laboratory Accreditation Program.
Learn More